After the FDA issues a warning letter, the recipient has 15 business days to respond in writing with a plan to fix the violations. Nearly 90% of firms meet that deadline. What follows is a structured process of correction, verification, and potential escalation that can take months or even years to fully resolve, depending on how quickly and thoroughly the company addresses the problems.
The 15-Day Response Window
Every warning letter spells out the specific violations the FDA found and instructs the company to respond within 15 business days of receiving it. That response needs to detail exactly what corrective actions the firm plans to take, not just acknowledge the problems. A vague promise to “look into it” won’t satisfy the agency. The FDA expects a concrete plan with timelines: which processes will change, what new procedures will be put in place, and when each fix will be completed.
Responding on time matters, but it’s only the first step. The letter itself is public. The FDA posts all warning letters to a searchable online database, meaning competitors, investors, customers, and journalists can read the full text. For publicly traded companies, a warning letter often triggers immediate stock price movement and may require a formal disclosure to shareholders through securities filings.
How the FDA Verifies Corrections
Writing a good response letter doesn’t close the case. The FDA won’t take a company’s word that problems have been fixed. The standard for verification is a follow-up inspection, where FDA investigators return to the facility to confirm that the corrective actions described on paper have actually been implemented on the ground.
A written promise that some action will be or has been taken is explicitly not enough for the FDA to consider the matter resolved. The agency needs to see physical evidence: updated standard operating procedures being followed, new equipment installed, retrained staff performing tasks correctly, revised testing protocols producing compliant results. The gap between the original letter and a successful follow-up inspection often stretches several months, sometimes longer if the violations are complex or the company’s initial fixes fall short.
Getting a Close-Out Letter
The formal end of a warning letter comes when the FDA issues a close-out letter. This happens only after the agency has completed its own evaluation of the corrective actions and confirmed they adequately address every violation in the original warning letter. In practice, that usually means passing a follow-up inspection.
There are two important caveats. First, if the warning letter contains violations that are not correctable by their nature, no close-out letter will ever be issued. Second, the timeline is entirely in the FDA’s hands. There is no guaranteed deadline for the agency to conduct its follow-up inspection or issue the close-out. Companies sometimes operate under an open warning letter for a year or more while awaiting final resolution.
What Happens to Pending Applications
An active warning letter can freeze a company’s ability to get new products approved. For generic drug manufacturers, the FDA will not engage in application-related discussions during post-warning-letter meetings, even if application reviewers are present. The meetings are limited to discussing how the facility will correct its violations.
Companies caught in this situation sometimes work around it by transferring manufacturing to a different, compliant facility and amending their pending applications to reflect the change. The FDA has published specific guidance on how to make these facility changes in pending applications. But switching manufacturing sites is expensive and time-consuming, so an unresolved warning letter can delay a product launch by months or years.
Escalation If Violations Aren’t Fixed
When a company fails to correct the problems outlined in a warning letter, the FDA has a range of progressively more serious enforcement tools. The agency builds its case by documenting that it gave the company a fair chance to fix things voluntarily, through the warning letter, inspection reports, meetings, and phone calls, before seeking court involvement.
The most common next step is an injunction, a court order that can force a company to stop manufacturing, halt distribution, or shut down specific operations until violations are corrected. The FDA favors injunctions when there are long-standing, chronic violations that the company has repeatedly promised to fix but hasn’t. A history of broken promises actually strengthens the FDA’s legal position, because it demonstrates the company’s resistance to voluntary compliance.
If a company violates the terms of a court injunction, the consequences escalate further. The FDA can pursue:
- Seizure of products that violate FDA regulations
- Civil contempt proceedings for violating the court order
- Criminal contempt charges, which can result in fines or imprisonment
- Criminal prosecution of responsible individuals
- Civil money penalties, particularly for medical device and tobacco violations
- Withdrawal of approved applications, effectively pulling a company’s products from the market
Impact on Imports
For companies that ship products into the United States, a warning letter can trigger placement on an FDA Import Alert. When a firm or product appears on the red or yellow list of an import alert, the FDA can detain future shipments at the border without physically examining them. This is known as “detention without physical examination,” and it effectively blocks a company’s products from entering the U.S. market until the violations are resolved.
Import alerts are public, just like warning letters, so they’re visible to the entire import community. For international manufacturers, this can be more damaging than the warning letter itself, because it cuts off access to one of the world’s largest consumer markets in real time rather than just threatening future action.
Realistic Timeline for Resolution
The fastest path from warning letter to close-out takes roughly six to twelve months: a few weeks to respond, several months to implement corrections, then time for the FDA to schedule and conduct a follow-up inspection. In practice, many cases take longer. Companies that underestimate the scope of required changes, or that address surface-level symptoms without fixing root causes, often fail their first follow-up inspection and restart the clock.
During the entire period that a warning letter remains open, the company operates under its shadow. New product approvals may be stalled, import shipments may be blocked, and the letter sits in a public database for anyone to find. The business pressure to resolve a warning letter quickly is enormous, but cutting corners on corrections only invites escalation. The FDA’s enforcement playbook is designed to reward genuine, verified fixes and to progressively tighten the screws on companies that don’t deliver them.